US/UK/Canada

Share

Pick a time period -
Tags ( Active)

NASDAQ STOCKHOLM HAS APPROVED APPLICATION FOR DE-LISTING

Allenex AB (publ) announced on 20 May 2016 that the company had decided to apply for de-listing of the Allenex share from Nasdaq Stockholm. The application has now been approved. The last day of trading in the Allenex share will be Wednesday 8 June 2016. For more information please contact: Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se  Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 25,

CAREDX INITIATES COMPULSORY ACQUISITION PROCEEDINGS AND ALLENEX FILES FOR DE-LISTING

CareDx, Inc ("CareDx") announced on 8 April 2016 that the company completes its public offer to the shareholders of Allenex AB (publ), ("Allenex"). After completion of the offer, CareDx holds approximately 98.3 percent of the shares of Allenex and has notified Allenex’ board of directors that CareDx has resolved to initiate compulsory acquisition proceedings regarding the remaining shares. In light of the above, Allenex’ board of directors does not consider it motivated for Allenex to remain a listed company and has therefore decided to apply for de-listing of the Allenex share from

INTERIM REPORT JAN-MAR 2016

For the January-March period · Net sales for the period totaled SEK 32.6 million (33.7). · Operating profit (EBIT) for the period was SEK 1.7 million (5.8). · Operating margin for the period was 5 percent (17). · Earnings after tax for the period amounted to SEK 0.4 million (5.5). · Earnings per share, basic and diluted for the period was SEK 0.00 (0.05).  Significant events in the first quarter and after the end of the reporting period · On February 9, 2016, CareDx, Inc. announced revised terms of its offer to the shareholders of Allenex AB. The Board of Directors’

Earlier publication of Q1 report

Allenex AB (publ) is adjusting the Q1 report release date to the financial calendar of CareDx Inc. and will therefore publish the Q1 2016 report on May 6th at 12.30 CET. The previously communicated date for this report was May 19th 2016. For more information please contact:Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on April 27, 2016, at 13.00 CET.

OPERATING INCOME SEK 24.2 million (22.9) JAN-DEC 2015

YEAR-END REPORT 2015For the October-December period · Net sales for the period were SEK 34.7 million (30.7). · Operating income (EBIT) for the period was SEK 9.1 million (9.5). · Operating margin for the period was 26 percent (31). · Earnings after tax for the period amounted to SEK 5.6 million (7.2). · Earnings per share, basic and diluted, for the period were SEK 0.05 (0.05). For the January-December period · Net sales for the period were SEK 134.5 million (125.2). · Operating income (EBIT) for the period was SEK 24.2 million (22.9). · Operating margin for

STATEMENT BY THE BOARD OF DIRECTORS OF ALLENEX AB (PUBL) IN RELATION TO REVISED TERMS IN THE PUBLIC TAKEOVER OFFER FROM CAREDX, INC

Background CareDx, Inc (the “Bidder”) announced on 16 December 2015 a public takeover offer to the shareholders of Allenex AB (publ) (“Allenex”) to acquire all of the outstanding shares of Allenex (the “Offer”). With the exception of Midroc Invest AB, Fastpartner AB and Xenella Holding AB, the shareholders of Allenex were offered a cash consideration of 2.50 SEK per share (the “Cash Alternative”). As an alternative offer, a cash consideration of SEK 1.731 per share and 0.01298 shares in the Bidder per share in Allenex was offered (the “Mixed Alternative”), which at the time of the

STATEMENT BY THE BOARD OF DIRECTORS OF ALLENEX AB (PUBL) IN RELATION TO CAREDX INC’S PUBLIC TAKEOVER OFFER

The Board of Directors of Allenex AB (publ) unanimously recommends the shareholders to accept the public takeover offer made by CareDx, Inc.Background CareDx, Inc (the "Bidder"), listed on Nasdaq Global Market, USA, has today, through a press release, announced a public takeover offer to the shareholders of Allenex AB (publ), ("Allenex") to acquire all of the outstanding shares of Allenex (the “Offer”). With the exception of Midroc Invest AB, Fastpartner AB and Xenella Holding AB (jointly the “Majority Shareholders”) the shareholders of Allenex are offered a cash consideration of SEK 2.

corr: INTERIM REPORT JANUARY – SEPTEMBER 2015

For the July-September period · Net sales for the period were SEK 32.2 million (32.4). · Operating income (EBIT) for the period was SEK 5.1 million (7.3). · Operating margin for the period was 16 percent (22). · Earnings after tax for the period were SEK 3.6 million (6.4). · Earnings per share for the period, basic and diluted, were SEK 0.03 (0.05). For the January-September period · Net sales for the period were SEK 99.8 million (94.5). · Operating income (EBIT) for the period was SEK 15.1 million (13.4). · Operating margin for the period was 15 percent (14).

OPERATING INCOME SEK 10,0 million (6,2) JAN-JUN 2015

INTERIM REPORT JANUARY – JUNE 2015For the April-June period ·Net sales for the period were SEK 33.9 million (31.5). ·Operating income (EBIT) for the period was SEK 4.2 million (2.0). ·Operating margin for the period was 12 percent (6). ·Earnings after tax for the period were SEK 0.4 million (0.4). ·Earnings per share for the period, basic and diluted, were SEK 0.00 (0.00). For the January-June period ·Net sales for the period were SEK 67.6 million (62.1). ·Operating income (EBIT) for the period was SEK 10.0 million (6.2). ·Operating

OPERATING INCOME +38% JAN-MAR 2015

OPERATING INCOME +38% JAN-MAR 2015 INTERIM REPORT JANUARY-MARCH 2015. For the January-March period ·Net sales for the period were SEK 33.7 million (30.6). ·Operating income (EBIT) for the period was SEK 5.8 million (4.2). ·Operating margin for the period was 17 percent (14). ·Earnings after tax for the period were SEK 5.5 million (1.3). ·Earnings per share for the period, basic and diluted, were SEK 0.05 (0.01). Significant events in the first quarterAllenex acquired all minority holdings in the group from SSP Primers AB for SEK 20 million.

Allenex acquires all remaining minority interests in the group

Allenex AB (publ) (”Allenex”) has signed an agreement to acquire all SSP Primers AB’s ("SSP Primers") shares in Olerup SSP AB, AbSorber AB, Olerup International AB and Olerup Inc. The acquisition will make Allenex the sole owner of all companies in the Allenex group. At the same time, Allenex acquires SSP Primers’ claim on Olerup Inc. of about 4 million SEK. These acquisitions are financed by loans made available by the company's main bank and by payments from Allenex to SSP Primers over a period of three years.Pursuant to the agreement Allenex acquires 9% of Olerup SSP AB, 1.9% of AbSorber

OPERATING INCOME 22,9 MILLION (9,6) JAN – DEC 2014

YEAR END REPORT JAN – DEC 2014For the period October- December ·Net sales for the period amounted to SEK 30.7 million (29.4). ·Operating income (EBIT) for the period was SEK 9.5 million (2.2). ·Operating margin for the period was 31 percent (8). ·Earnings after tax for the period rose to SEK 7.2 million (0.1). ·Earnings per share for the period, basic and diluted, was SEK 0.05 (0.02). For the period January-December ·Net sales for the year amounted to SEK 125.2 million (111.8). ·Operating income (EBIT) for the year was SEK 22.9 million (9.

NET SALES +15% JANUARY - SEPTEMBER 2014

INTERIM REPORT JANUARY - SEPTEMBER 2014.For the July –September period          ·Net sales for the period rose to SEK 32.4 million (28.4). ·Operating income (EBIT) for the period was SEK 7.3 million (2.8). ·Operating margin for the period rose to 22 percent (9). ·Earnings after tax for the period was SEK 6.4 million (-0.3). ·Earnings per share for the period, basic and diluted, were SEK 0.05 (0.00). For the January – September period ·Net sales for the period rose to SEK 94.5 million (82.4). ·Operating income (EBIT) for the period was SEK

Allenex to launch new HLA typing technology in 2015

During 2014, Allenex has started the development of brand new HLA typing tests based on the method of real-time PCR. The aim is to launch the products during the second quarter of 2015. The advantage of the real-time PCR method is that it is simpler and faster compared to currently used HLA typing methods.  "We see great value in being able to offer Allenex customers worldwide HLA typing products based on the method of real-time PCR" says Allenex CEO Anders Karlsson, and he continues: "HLA typing based on the method of real-time PCR is more rapid and efficient. It is especially valuable

Sales +15% jan-jun 2014

Sales +15% jan-jun 2014 INTERIM REPORT JANUARY - JUNE 2014 For the April-June period ·Net sales for the period rose to SEK 31.5 million (27.2). ·Operating income (EBIT) for the period was SEK 2.0 million (2.6). ·Operating margin for the period was 6 percent (9). ·Earnings after tax for the period was SEK 0.4 million (2.5). ·Earnings per share for the period, basic and diluted, was SEK 0.00 (0.02). For the January-June period ·Net sales for the period rose to SEK 62.1 million (54.0). ·Operating profit (EBIT) for the period was SEK 6.2

Three new products will be launched globally.

Allenex (through the subsidiary Olerup SSP AB) has entered into an agreement with the Australian company Conexio Genomics Pty Ltd (”Conexio”) to the effect that the parties’ co-operation is deepened and extended in time. In May 2011 Allenex announced a five year exclusive and global marketing and sales agreement with Conexio for SBT Resolver™ for HLA typing using the SBT technology. Software for sequence analysis was also included in the agreement. Allenex and Conexio have now decided to prolong the agreement for an additional period of two years, which means that the co-operation is

Sales +14% Jan – Mar 2014

For the January-March period ·Net sales for the period were SEK 30.6 million (26.8). ·Operating income (EBIT) for the period was SEK 4.2 million (2.0). ·Operating margin for the period was 13 percent (7). ·Earnings after tax for the period totaled SEK 1.3 million (-0.1). ·Earnings per share for the period, basic and diluted, was SEK 0.01 (0.00). President and CEO Anders Karlsson's commentary on the first quarter 2014: “The first quarter saw continued strong growth in the U.S., as well as a clear improvement in sales in Europe compared to the same

ALLENEX YEAR-END REPORT 2013

For the fourth quarter October-December ·Net sales for the quarter amounted to SEK 29.4 million (27.4). Sales were impacted by a positive currency effect of SEK 0.3 million compared to the same period last year. ·Operating income (EBIT) for the quarter was SEK 2.2 million (0.6), with currency effects having a positive impact of SEK 0.6 million compared to the same period last year. ·Operating margin for the quarter was 8 percent (2). ·Earnings after tax for the quarter were SEK 0.1 million (0.9). ·Earnings per share for the quarter, basic and diluted, were

INTERIM REPORT JANUARY - SEPTEMBER 2013

For the third quarter, July-September · Net sales for the quarter amounted to SEK 28.4 million (26.7). Sales were impacted by a positive currency effect of SEK 0.3 million compared to the same period last year. · Operating income (EBIT) for the quarter was SEK 2.8 million (1.3), with currency effects having a negative impact of SEK 1.0 million compared to the same period last year. · Operating margin for the quarter was 9 percent (4). · Loss after tax for the quarter was SEK 0.3 million (-1.8). · Earnings per share for the quarter, basic and diluted, were SEK 0.00 (-0.01).

Allenex appoints new Head of Olerup Inc. in U.S.

Gordon Hill has been appointed National Sales Director and he becomes responsible for sales and operations at Olerup Inc., an Allenex AB subsidiary. He comes to Allenex from a leadership position within Technical Sales at the current U.S. market leader within transplant diagnostics, One Lambda / Thermo Fisher. Through his previous work Gordon Hill has a large network within the North American transplant laboratories. "Gordon Hill is a strong addition for us and I am convinced that he will lead Olerup Inc. on a continued sales growth path in the US thanks to his solid experience in both

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media